BACKGROUND: Epidemiologic studies have reported increased risk of lymphohematopoietic cancers, lung cancer, and pancreatic cancer after exposure to styrene, although findings across studies are not consistent. METHODS: We update a large study of reinforced plastic industry workers with relatively high exposures to styrene, examining cancer risks associated with exposure levels. The study includes 15,826 workers who were exposed between 1948 and 1977 with vital-status follow-up from 1948 to 2008. We examine mortality rates associated with cumulative exposure, duration of exposure, peak exposures, average exposure, and time since first exposure to styrene. Exposure estimates were truncated starting in 1977, the period with the lowest exposures, leaving 27% of the study group with incomplete work histories. RESULTS: The standardized mortality ratios were 0.84 (95% confidence interval = 0.69-1.02) for all lymphatic and hematopoietic cancers combined, 0.72 (0.50-1.00) for non-Hodgkin lymphoma, and 0.84 (0.60-1.14) for leukemia. There was no trend with either cumulative exposure to styrene or number of peaks. Pancreatic cancer deaths were at expected levels (0.96 [0.73-1.22]). There were more lung cancer deaths than expected (1.34 [1.23-1.46]), although with a marked inverse trend with cumulative exposure. CONCLUSION: We found no coherent evidence that styrene exposure increases risk from cancers of the lymphatic and hematopoietic tissue, pancreas, or lung.
BACKGROUND: Epidemiologic studies have reported increased risk of lymphohematopoietic cancers, lung cancer, and pancreatic cancer after exposure to styrene, although findings across studies are not consistent. METHODS: We update a large study of reinforced plastic industry workers with relatively high exposures to styrene, examining cancer risks associated with exposure levels. The study includes 15,826 workers who were exposed between 1948 and 1977 with vital-status follow-up from 1948 to 2008. We examine mortality rates associated with cumulative exposure, duration of exposure, peak exposures, average exposure, and time since first exposure to styrene. Exposure estimates were truncated starting in 1977, the period with the lowest exposures, leaving 27% of the study group with incomplete work histories. RESULTS: The standardized mortality ratios were 0.84 (95% confidence interval = 0.69-1.02) for all lymphatic and hematopoietic cancers combined, 0.72 (0.50-1.00) for non-Hodgkin lymphoma, and 0.84 (0.60-1.14) for leukemia. There was no trend with either cumulative exposure to styrene or number of peaks. Pancreatic cancer deaths were at expected levels (0.96 [0.73-1.22]). There were more lung cancer deaths than expected (1.34 [1.23-1.46]), although with a marked inverse trend with cumulative exposure. CONCLUSION: We found no coherent evidence that styrene exposure increases risk from cancers of the lymphatic and hematopoietic tissue, pancreas, or lung.
Authors: Randall J Nett; Jean M Cox-Ganser; Ann F Hubbs; Avima M Ruder; Kristin J Cummings; Yuh-Chin T Huang; Kathleen Kreiss Journal: Am J Ind Med Date: 2017-02 Impact factor: 2.214
Authors: Anna-Binney McCague; Jean M Cox-Ganser; Joshua M Harney; K Udeni Alwis; Benjamin C Blount; Kristin J Cummings; Nicole Edwards; Kathleen Kreiss Journal: Am J Ind Med Date: 2015-08-25 Impact factor: 2.214
Authors: Dana Loomis; Neela Guha; Manolis Kogevinas; Vincenzo Fontana; Valerio Gennaro; Henrik A Kolstad; Damien Martin McElvenny; Markku Sallmén; Rodolfo Saracci Journal: Occup Environ Med Date: 2018-04-17 Impact factor: 4.402
Authors: George Cruzan; James S Bus; Marcy I Banton; Satinder S Sarang; Robbie Waites; Debra B Layko; James Raymond; Darol Dodd; Melvin E Andersen Journal: Toxicol Sci Date: 2017-10-01 Impact factor: 4.849